ProPhase Labs (NASDAQ:PRPH) was downgraded by stock analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Tuesday, TheStreetRatingsTable reports.
NASDAQ:PRPH remained flat at $$2.07 on Tuesday. 900 shares of the company’s stock were exchanged, compared to its average volume of 9,033. ProPhase Labs has a 12-month low of $2.01 and a 12-month high of $4.00. The company has a 50 day moving average price of $2.70.
ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.09) earnings per share for the quarter. ProPhase Labs had a negative return on equity of 14.54% and a negative net margin of 23.26%. The business had revenue of $2.32 million for the quarter.
A hedge fund recently bought a new stake in ProPhase Labs stock. Dimensional Fund Advisors LP acquired a new stake in ProPhase Labs Inc (NASDAQ:PRPH) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,817 shares of the company’s stock, valued at approximately $34,000. Dimensional Fund Advisors LP owned 0.09% of ProPhase Labs at the end of the most recent quarter. Institutional investors and hedge funds own 4.31% of the company’s stock.
About ProPhase Labs
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Featured Article: Preferred Stock
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.